Trial Profile
A Phase III , open-label study of KRP-AM1977Y for patients with respiratory tract infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Lascufloxacin (Primary)
- Indications Respiratory tract infections
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical
- 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2016 Status changed from not yet recruiting to recruiting.
- 05 Jul 2016 New trial record